The semaglutide cohort ( n = 1470) compared with the non-GLP-1RA anti-obesity medications cohort ( n = 2784) was older, included more women, had a higher prevalence of severe obesity and obesity-associated comorbidities including T2DM and lower prevalence of adverse socioeconomic determinants of health, mental disorders, and substance use disorders
Addressing and reducing side effects is a pivotal aspect of medical treatments and the advancement of new pharmaceuticals [41, 42]
For instance, we note that certain specific bacterial genera demonstrate favorable therapeutic effects against particular liver diseases, thereby laying a theoretical foundation for future scientific research targeting specific GM taxa for the treatment of specific liver conditions
A recent study of veterinary probiotics showed that only 27% contained the (live) actual strains advertised at the correct dose, and many were dead, or non-viable, and in some cases contaminated with unrelated bacteria or yeast [24]